AXIM BIOTECHNOLOGIES Business Summary

AXIM Biotechnologies, Inc. (AXIM) is a vertically integrated diagnostic healthcare company that generates revenue through the development, manufacturing, and commercialization of rapid point-of-care (POC) diagnostic tests and research services. The company’s primary business segments include its ophthalmology division, branded as Axim Eye, which utilizes a recurring revenue model based on disposable single-use cassettes for its TearScan® Lactoferrin and IgE tests, and its oncology/research arm, Sapphire Biotech, which provides custom biomarker research and assay development. AXIM’s competitive strategy focuses on the niche ocular biomarker market, specifically targeting Dry Eye Disease (DED) and allergic conjunctivitis. In the broader biotechnology and diagnostic landscape, AXIM competes with firms such as Dermavant Sciences, Moderna, and Jazz Pharmaceuticals, positioning itself as a specialized micro-cap provider of low-cost, high-speed diagnostic solutions compared to larger, more diversified pharmaceutical entities. Leadership is currently headed by CEO and President Catalina Valencia, a serial entrepreneur and attorney who previously served as senior in-house counsel at Genentech and founded Sapphire Biotech before its acquisition by AXIM. The executive team includes Founder and Chairman Dr. George E. Anastassov, a physician and surgeon with an extensive background in cannabinoid-based therapeutics, and Chief Technology Officer Lekhram Changoer, who brings over 25 years of experience in pharmaceutical product development. The company’s board is further strengthened by Director Robert Cunningham, an expert in venture capital and financial services. A notable strategic investor and long-term partner is Medical Marijuana, Inc. (MJNA), which recently entered into a strategic alliance with AXIM in early 2026 to co-develop applications for water-soluble cannabinoid patents, providing AXIM with significant industry-specific capital and distribution networks.